These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 11745416

  • 1. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo.
    Itami A, Watanabe G, Shimada Y, Hashimoto Y, Kawamura J, Kato M, Hosotani R, Imamura M.
    Int J Cancer; 2001 Nov 01; 94(3):370-6. PubMed ID: 11745416
    [Abstract] [Full Text] [Related]

  • 2. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
    Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y.
    Cancer Res; 2000 Oct 01; 60(19):5558-64. PubMed ID: 11034103
    [Abstract] [Full Text] [Related]

  • 3. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
    Takeuchi S, Okumura T, Motomura W, Nagamine M, Takahashi N, Kohgo Y.
    Jpn J Cancer Res; 2002 Jul 01; 93(7):774-82. PubMed ID: 12149143
    [Abstract] [Full Text] [Related]

  • 4. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
    Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, Sasatomi K, Kimura R, Hashimoto O, Ueno T, Yano H, Kojiro M, Sata M.
    Hepatology; 2001 May 01; 33(5):1087-97. PubMed ID: 11343236
    [Abstract] [Full Text] [Related]

  • 5. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.
    Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD.
    Neoplasia; 1999 Oct 01; 1(4):330-9. PubMed ID: 10935488
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells.
    Hashimoto K, Ethridge RT, Evers BM.
    Int J Gastrointest Cancer; 2002 Oct 01; 32(1):7-22. PubMed ID: 12630765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
    Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M.
    Hepatology; 2003 May 01; 37(5):1086-96. PubMed ID: 12717389
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
    Wakino S, Kintscher U, Liu Z, Kim S, Yin F, Ohba M, Kuroki T, Schönthal AH, Hsueh WA, Law RE.
    J Biol Chem; 2001 Dec 14; 276(50):47650-7. PubMed ID: 11598137
    [Abstract] [Full Text] [Related]

  • 11. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
    Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, Okumura T.
    Int J Cancer; 2004 Jan 01; 108(1):41-6. PubMed ID: 14618613
    [Abstract] [Full Text] [Related]

  • 12. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
    Tsujie M, Nakamori S, Okami J, Takahashi Y, Hayashi N, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.
    Int J Oncol; 2003 Aug 01; 23(2):325-31. PubMed ID: 12851681
    [Abstract] [Full Text] [Related]

  • 13. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
    Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP.
    Cancer Res; 1998 Aug 01; 58(15):3344-52. PubMed ID: 9699665
    [Abstract] [Full Text] [Related]

  • 14. PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.
    Kitamura S, Miyazaki Y, Hiraoka S, Nagasawa Y, Toyota M, Takakura R, Kiyohara T, Shinomura Y, Matsuzawa Y.
    Int J Cancer; 2001 Nov 01; 94(3):335-42. PubMed ID: 11745411
    [Abstract] [Full Text] [Related]

  • 15. Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer.
    Sasaki T, Fujimoto Y, Tsuchida A, Kawasaki Y, Kuwada Y, Chayama K.
    Pathobiology; 2001 Nov 01; 69(5):258-65. PubMed ID: 12107343
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines.
    Kato M, Nagaya T, Fujieda M, Saito K, Yoshida J, Seo H.
    Jpn J Cancer Res; 2002 Jun 01; 93(6):660-6. PubMed ID: 12079514
    [Abstract] [Full Text] [Related]

  • 18. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
    Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ, Law RE.
    Biochem Biophys Res Commun; 2001 Sep 07; 286(5):916-22. PubMed ID: 11527386
    [Abstract] [Full Text] [Related]

  • 19. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells.
    Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, Mori M.
    Gut; 2002 Apr 07; 50(4):563-7. PubMed ID: 11889080
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.